EP0347056B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Essential fatty acid compositions
Assignee: Scarista Ltd
•
Filing: 1989-05-26
•
Granted: 1993-04-07
•
Expires: 2009-05-26
Abstract
Abstract Method of, and preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher n-6 series acids with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10 mg and 50 g of each acid and with Vitamin E in addition.
Inventors
- 👤 David Frederick Scotia Pharmeutical Horrobin
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 08:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/33; A61K31/335; A61K31/35; A61K31/352; A61K31/353; A61K31/355; A61P; A61P17/00; A61P25/00; A61P25/18; A61P29/00; A61P3/00; A61P3/06; A61P37/00; A61P37/08
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
81 words
Process for the preparation of a medicament for treating tardive dyskinesia which comprises mixing an essential fatty acid selected from GLA and higher n-6 series acids and an essential fatty acid selected from stearidonic acid and higher n-3 series acids, in amounts suited to administration of effective daily amounts of 10 mg to 50 g of each acid, together with Vitamin E, present in an amount of 3 % by weight or more based on the total amount of said acids.
Claim 2
Dependent Claim
34 words
A process according to claim 1, wherein the essential fatty acids comprise an n-6 EFA selected from GLA, DGLA and AA and an n-3 EFA selected from stearidonic acid, EPA, 22:5 n-3 and DHA.
References Cited (Backward Citations)
EP0273407A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.